Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice

Understanding of the importance of the normal intestinal microbial community in regulating microbial homeostasis, host metabolism, adaptive immune responses, and gut barrier functions has opened up the possibility of manipulating the microbial composition to modulate the activity of various intestin...

Full description

Bibliographic Details
Main Authors: Maroun Bou Zerdan, Stephanie Niforatos, Sandy Nasr, Dayana Nasr, Mulham Ombada, Savio John, Dibyendu Dutta, Seah H. Lim
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/3/691
_version_ 1797488713248276480
author Maroun Bou Zerdan
Stephanie Niforatos
Sandy Nasr
Dayana Nasr
Mulham Ombada
Savio John
Dibyendu Dutta
Seah H. Lim
author_facet Maroun Bou Zerdan
Stephanie Niforatos
Sandy Nasr
Dayana Nasr
Mulham Ombada
Savio John
Dibyendu Dutta
Seah H. Lim
author_sort Maroun Bou Zerdan
collection DOAJ
description Understanding of the importance of the normal intestinal microbial community in regulating microbial homeostasis, host metabolism, adaptive immune responses, and gut barrier functions has opened up the possibility of manipulating the microbial composition to modulate the activity of various intestinal and systemic diseases using fecal microbiota transplant (FMT). It is therefore not surprising that use of FMT, especially for treating relapsed/refractory <i>Clostridioides difficile</i> infections (CDI), has increased over the last decade. Due to the complexity associated with and treatment for these diseases, patients with hematologic and oncologic diseases are particularly susceptible to complications related to altered intestinal microbial composition. Therefore, they are an ideal population for exploring FMT as a therapeutic approach. However, there are inherent factors presenting as obstacles for the use of FMT in these patients. In this review paper, we discussed the principles and biologic effects of FMT, examined the factors rendering patients with hematologic and oncologic conditions to increased risks for relapsed/refractory CDI, explored ongoing FMT studies, and proposed novel uses for FMT in these groups of patients. Finally, we also addressed the challenges of applying FMT to these groups of patients and proposed ways to overcome these challenges.
first_indexed 2024-03-10T00:06:15Z
format Article
id doaj.art-669d46374dcc41d89b2cd935a42efcad
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-10T00:06:15Z
publishDate 2022-01-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-669d46374dcc41d89b2cd935a42efcad2023-11-23T16:07:07ZengMDPI AGCancers2072-66942022-01-0114369110.3390/cancers14030691Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and PracticeMaroun Bou Zerdan0Stephanie Niforatos1Sandy Nasr2Dayana Nasr3Mulham Ombada4Savio John5Dibyendu Dutta6Seah H. Lim7Division of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USAUnderstanding of the importance of the normal intestinal microbial community in regulating microbial homeostasis, host metabolism, adaptive immune responses, and gut barrier functions has opened up the possibility of manipulating the microbial composition to modulate the activity of various intestinal and systemic diseases using fecal microbiota transplant (FMT). It is therefore not surprising that use of FMT, especially for treating relapsed/refractory <i>Clostridioides difficile</i> infections (CDI), has increased over the last decade. Due to the complexity associated with and treatment for these diseases, patients with hematologic and oncologic diseases are particularly susceptible to complications related to altered intestinal microbial composition. Therefore, they are an ideal population for exploring FMT as a therapeutic approach. However, there are inherent factors presenting as obstacles for the use of FMT in these patients. In this review paper, we discussed the principles and biologic effects of FMT, examined the factors rendering patients with hematologic and oncologic conditions to increased risks for relapsed/refractory CDI, explored ongoing FMT studies, and proposed novel uses for FMT in these groups of patients. Finally, we also addressed the challenges of applying FMT to these groups of patients and proposed ways to overcome these challenges.https://www.mdpi.com/2072-6694/14/3/691fecal microbiota transplanthematologic diseasesoncologic diseasesoutcomechallenges
spellingShingle Maroun Bou Zerdan
Stephanie Niforatos
Sandy Nasr
Dayana Nasr
Mulham Ombada
Savio John
Dibyendu Dutta
Seah H. Lim
Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
Cancers
fecal microbiota transplant
hematologic diseases
oncologic diseases
outcome
challenges
title Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
title_full Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
title_fullStr Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
title_full_unstemmed Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
title_short Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
title_sort fecal microbiota transplant for hematologic and oncologic diseases principle and practice
topic fecal microbiota transplant
hematologic diseases
oncologic diseases
outcome
challenges
url https://www.mdpi.com/2072-6694/14/3/691
work_keys_str_mv AT marounbouzerdan fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice
AT stephanieniforatos fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice
AT sandynasr fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice
AT dayananasr fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice
AT mulhamombada fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice
AT saviojohn fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice
AT dibyendudutta fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice
AT seahhlim fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice